Antiandrogen Withdrawal in Treating Patients With Hormone-Refractory Prostate Cancer
Study Information
Alliance Study ID: CALGB-9583
NCT Study ID (ClinicalTrials.gov): NCT00002760
Alliance Committee: Genitourinary Cancer
Disease or Cancer Type: Prostate Cancer
Alliance Study Chair: Eric Small, MD
Status: COMPLETED
Study Description
RATIONALE: Antiandrogen withdrawal may be an effective treatment for prostate cancer.
PURPOSE: Randomized phase III trial to study the effectiveness of ketoconazole and hydrocortisone for antiandrogen withdrawal in treating men with prostate cancer that is refractory to hormone therapy.
Related Publications
For publications related to this and other clinical trials, visit the Alliance Publications Application.
Data Sources & Contacts
Full trial details
For more Information